Active oncological conditions
Stem cells can stimulate the growth of existing tumours through growth factors and angiogenesis.
Methods of administration / 03
There is no "one shot for all". The choice of administration route is a key clinical decision. Systemic effect via the bloodstream, direct delivery into the CNS or targeted local injection — our academic board selects the optimal protocol for your diagnosis.
Cell types
Three types of biomaterial with different mechanisms of action. The specific choice depends on the diagnosis and is selected individually.
UC-MSC
Young multipotent cells isolated from Wharton's jelly of the umbilical cord. High proliferative activity and low immunogenicity.
P-MSC
Placenta-derived cells with pronounced immunomodulatory potential. Used in autoimmune and inflammatory conditions.
Exosomes
Extracellular vesicles 30–150 nm in size carrying signalling molecules. Capable of crossing the blood-brain barrier.
Administration routes
From systemic intravenous infusion to precise intrathecal delivery into the CNS. The route is dictated by the diagnosis, not by preference.
The most studied and widely used route. Cells distribute throughout the body via the bloodstream, delivering a powerful systemic effect.
What to know
Cells are injected directly into the subarachnoid space via lumbar puncture. The goal is to bypass the blood-brain barrier and deliver cells into the central nervous system.
What to know
Direct injection into a specific organ or damaged tissue. Used when maximum cell concentration in the affected area is required.
What to know
An advanced non-invasive method. Exosomes pass through the olfactory and trigeminal nerves directly into the brain — no needle, no hospitalisation, delivered as nasal drops.
What to know
A combination of two routes for maximum effect. Most often intravenous administration for systemic support plus intrathecal for direct CNS impact.
What to know
Indications
Six main areas where Hanshi United has accumulated experience. Every case is reviewed individually by the academic board.
Stroke, Alzheimer's and dementia, Parkinson's, autism, cerebral palsy, epilepsy
Myocardial infarction, ischaemic heart disease, heart failure, dilated cardiomyopathy
Type 1 and Type 2 diabetes, diabetic complications
Liver cirrhosis and fibrosis, liver failure, Crohn's disease, ulcerative colitis
Osteoarthritis, avascular necrosis of the femoral head, osteoporosis, delayed fracture healing
Systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma
Detailed information on each diagnosis is available in the Treatments section.
Important · Contraindications
The conditions below either preclude cell therapy or require particular caution. The final decision is made by a physician after a full examination.
Stem cells can stimulate the growth of existing tumours through growth factors and angiogenesis.
During an active infection, cell therapy can worsen the condition and reduce the effectiveness of the body's own immune response.
The effect of stem cell therapy on the foetus and the breastfed infant has not been studied in clinical trials.
Any injectable cell-administration route carries a bleeding risk when haemostasis is impaired. Prior correction is required.
A free consultation — send your case, and the academic board will provide a preliminary assessment and recommend an optimal administration route.
We use cookies and analytics services to improve the website experience. Privacy Policy